"I am very excited about the biologic candidates being developed at Bioquark Inc. and their very novel approach to human regeneration and disease reversion." - Dr. Luis Martinez, MD. MPH
Philadelphia, PA (PRWEB) March 13, 2014
Bioquark, Inc., (http://www.bioquark.com) a company focused on the development of combinatorial biologics for regeneration and disease reversion in human organs and tissues, today announces the appointment of Dr. Luis Martinez, MD, MPH, as VP of Global Operations.
“We are honored to have someone with Dr. Martinez’s experience join us as we execute on a globalized strategy in regenerative medicine,” said Ira S. Pastor, CEO, Bioquark Inc. “His broad clinical experience in applied regenerative medicine and cellular therapies make him a very valuable addition to the Bioquark team.”
Dr. Martinez is a regenerative medicine and cell therapy specialist with over 10 years of experience in the clinical setting. He is currently the President of Elite Regenerative Medicine Group, a premier treatment and research center specializing in cell therapy applications for therapeutic, regenerative and preventive purposes. Dr. Martinez obtained his medical degree, as well as his Master of Public Health, at the Ponce School of Medicine and Health Sciences, and completed his residency at the prestigious University of Pennsylvania. He also completed a fellowship in biosecurity with the UPMC Center for Health Security. He is currently a clinical instructor at the Ponce School of Medicine and Health Sciences and is a board certified physician. Dr. Martinez also serves as vice-president of the XanoGene Anti-Aging Clinic and is President at Xyrion Medical, a biomedical consulting firm. He is a current consultant for multiple biomedical and pharmaceutical companies and conducts clinical research for various clients in the industry. Dr. Martinez is also a renowned international speaker, speaking at multiple venues for professional and academic organizations and he offers training to physicians in multiple applications of regenerative medicine, including Platelet Rich Plasma (PRP) therapy, adipose and bone marrow stem cell derived harvesting, preparation and therapeutic administration, as well as cytokine, growth factor and peptide therapies.
“I am very excited about the biologic candidates being developed at Bioquark Inc. and their very novel approach to human regeneration and disease reversion, which has broad clinical applicability towards a range of degenerative disorders," said Dr. Martinez. "I'm pleased to be joining the team and am looking forward to playing a more active role in this truly transformational platform."
About Bioquark, Inc.
Bioquark Inc. is focused on the development of biologic based products that have the ability to alter the regulatory state of human tissues and organs, with the goal of curing a wide range of diseases, as well as effecting complex regeneration. Bioquark is developing biological pharmaceutical candidates, as well as products for the global consumer health and wellness market segments.